Chronic Obstructive Pulmonary Disease Market Research Report - Forecast till 2030

Chronic obstructive pulmonary disease (COPD) Market Research Report Information By CPOD Type (Emphysema, Chronic Bronchitis), By Treatment Type (Drugs, Anti-Inflammatory Drugs, Surgery, Oxygen Therapy), By End Users (Hospitals & Clinics, Homecare Settings, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2030.

ID: MRFR/Pharma/1081-HCR | | Region: Global | 90 Pages         

Chronic Obstructive Pulmonary Disease (COPD) Market Speak to Analyst Request a Free Sample

Global Chronic Obstructive Pulmonary Disease (COPD) Market Overview


Chronic Obstructive Pulmonary Disease (COPD) Market Size was valued at USD 1.82 billion in 2021 and is projected to grow from USD 3.07 Billion in 2022 to USD 29.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.50% during the forecast period (2022 - 2030).Rise in prevalence of CPOD across the globe and the increase in adoption of more effective combination therapy are driving the market growth.
Chronic Obstructive Pulmonary Disease (COPD) Market
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Chronic Obstructive Pulmonary Disease (COPD) Market Trends



  • Rise in prevalence of CPOD across the globe to boost market growth


Chronic obstructive pulmonary disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management. Tobacco smoking could lead to COPD. The number of adults addicted to smoking has been increasing across the globe. Other risk factors include occupation and indoor air pollution. According to the World Health Organization (WHO), the primary cause of COPD is exposure to tobacco smoke. According to the organization, chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.23 million deaths in 2022. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC).


According to a report by the Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2022, the prevalence and burden of COPD are projected to increase in the near future due to continued exposure to COPD risk factors, rise in the incidence of interstitial lung diseases, and aging population across the world. This is anticipated to augment the Chronic Obstructive Pulmonary Disease Treatment (COPD) market in the near future. The graph that follows illustrates the crude and weighted prevalence of COPD, overall and in men and women. Age-specific prevalence of COPD in men and women. Bars represent the prevalence and error bars the 95% clinical informatics.


Chronic Obstructive Pulmonary Disease Treatment (COPD) Market Segment Insights


Chronic Obstructive Pulmonary Disease Treatment (COPD) Type Insights


The Chronic Obstructive Pulmonary Disease Treatment (COPD) market segmentation, based on type, includes Emphysema, and Chronic Bronchitis. The chronic bronchitis segment held the majority share in 2021 in respect to the Chronic Obstructive Pulmonary Disease Treatment (COPD) market revenue. This is primarily owing to the growing incidence and prevalence of chronic bronchitis worldwide due to the rise in the consumption of cigarettes and the increase in industrialization, which results in air pollution and the release of harmful gases into the environment.


June 2022: AstraZeneca announced a plan to build a manufacturing unit in Qingdao, China, to produce its Breztri aerosol inhalant COPD treatment, which was recently added to the country’s National Reimbursement Drug List. Also, the company announced (in Chinese) during a meeting with local community officials but did not provide details on cost, scale, or completion date. Additionally, AstraZeneca said, that it would set up a regional headquarters in Qingdao and an innovation center focusing on rare diseases as part of its efforts to promote biomedical innovation in Qingdao.


July 2021: AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been approved and granted Priority Review for the treatment of asthma by the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.


Chronic Obstructive Pulmonary Disease Treatment (COPD) Treatment Type Insights


The Chronic Obstructive Pulmonary Disease Treatment (COPD) market segmentation, based on treatment type, includes drugs, surgery, and oxygen therapy. The drugs segment held the majority share in 2021 in respect to the Chronic Obstructive Pulmonary Disease Treatment (COPD) market revenue. This is primarily owing to the increasing use of drugs as the first line of treatment for COPD to make breathing easier by widening airways. Additionally, it is bifurcated into bronchodilator monotherapy, and anti-inflammatory drugs. Bronchodilator monotherapy further bifurcated into Short-Acting Beta2-Agonists (SABAs), Long-Acting Beta2-Agonists (LABAs), and Anti-Cholinergic Agent and anti-inflammatory drugs further bifurcated into oral and inhaled corticosteroids, and anti-leukotrienes.


Moreover, the oxygen therapy market is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the factors such as the rapid growth of the geriatric population the development of respiratory disorders, the rising prevalence of tobacco smoking, the increase in the usage of home-based oxygen therapy, and technological advancements. Hence, rising treatment of Chronic Obstructive Pulmonary Disease Treatment (COPD) positively impacts the market growth.


Chronic Obstructive Pulmonary Disease Treatment (COPD) End User Insights


The Chronic Obstructive Pulmonary Disease Treatment (COPD) market data has been bifurcated by surgery into hospitals & clinics, homecare settings, and others. The hospital & clinics segment dominated the market in 2021. This is primarily owing to the growing number of patients suffering from chronic respiratory diseases and rising awareness about these diseases. Furthermore, the availability of various diagnostics and treatment facilities and higher purchasing power has contributed to the segment’s growth.


November 2021: AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for USD 270 Million. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).


Figure 2: Chronic Obstructive Pulmonary Disease Treatment (COPD) Market, by End User, 2021 & 2030 (USD Billion)
Chronic Obstructive Pulmonary Disease Treatment (COPD) Market, by End User, 2021 & 2030
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Chronic Obstructive Pulmonary Disease Treatment (COPD) Regional Insights


By Region, the study segments the market into North America, Europe, Asia-Pacific and Rest of the World. North America Chronic Obstructive Pulmonary Disease Treatment (COPD) held the largest market share in 2021. This is attributed to the increased investment in R&D activities to develop innovative drugs for treating diseases. Also, the rise in incidence and prevalence of chronic respiratory diseases, technological advancement, growing healthcare sectors, and massive presence of leading market players are some of the major factors that boost the COPD Market in the region.


Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3: CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT (COPD) MARKET SHARE BY REGION 2021 (%)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT (COPD) MARKET SHARE BY REGION 2021
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe Chronic Obstructive Pulmonary Disease Treatment (COPD) market accounts for the second-largest market share due to the well-developed healthcare infrastructure and an increase in the incidence of chronic obstructive pulmonary diseases are propelling the COPD treatment market in the region. Further, the Germany Chronic Obstructive Pulmonary Disease Treatment (COPD) market held the largest market share, and the UK Chronic Obstructive Pulmonary Disease Treatment (COPD) market was the fastest growing market in the European region.


The Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment (COPD) market is expected to grow with a significant share. This is due to the untapped chronic obstructive pulmonary disease treatment market compared to developed regions. Therefore, Asia Pacific offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the chronic obstructive pulmonary disease treatment market in the region.


Moreover, China Chronic Obstructive Pulmonary Disease Treatment (COPD) market held the largest market share, and the India Chronic Obstructive Pulmonary Disease Treatment (COPD) market was the fastest growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2022–2030.


Chronic Obstructive Pulmonary Disease Treatment (COPD) Key Market Players & Competitive Insights


Major market players are spending a lot of money on R&D to increase their product lines, which will help the Chronic Obstructive Pulmonary Disease Treatment (COPD) market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Chronic Obstructive Pulmonary Disease (COPD) industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.


One of the primary business strategies adopted by manufacturers in the Chronic Obstructive Pulmonary Disease Treatment (COPD) industry to benefit clients and expand the Chronic Obstructive Pulmonary Disease Treatment (COPD) market sector is to manufacture locally to reduce operating costs. In recent years, Chronic Obstructive Pulmonary Disease (COPD) has provided medicine with some of the most significant benefits.


Alembic Pharmaceuticals Ltd. is a leading pharmaceutical company committed to develop, manufacture and market pharmaceutical products, pharmaceutical substances, and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs. In May 2022, Alembic Pharmaceuticals Ltd., a pharmaceutical company, received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.


Key Companies in the Chronic Obstructive Pulmonary Disease Treatment (COPD) market includes




  • AstraZeneca (UK)




  • Abbott Laboratories (US)




  • Dr. Reddy’s Laboratories Ltd (India)




  • GlaxoSmithKline (UK)




  • F. Hoffmann-La Roche Ltd (Switzerland)




  • Almirall (Spain)




  • Boehringer Ingelheim (Germany)




  • Pfizer Inc. (US)




  • Novartis AG (Switzerland)




  • Astellas Pharma (Japan)




Chronic Obstructive Pulmonary Disease (COPD) Industry Developments


October 2021: Mylan Pharmaceuticals received the FDA approval for its investigational new drug application (ANDA) for Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol). The first approved generic version of AstraZeneca's Symbicort. It is also anticipated to be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).


January 2019: CHIESI Farmaceutici S.p.A. entered into an exclusive license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. The agreement is aimed at developing innovative molecules for usage in the treatment of respiratory diseases.


June 2022: Verona Pharma, announced the completion of the patient enrolment, with more than 800 subjects involved in its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.


Chronic Obstructive Pulmonary Disease Treatment (COPD) Market Segmentation


Chronic Obstructive Pulmonary Disease Treatment (COPD) Type Outlook




  • Emphysema




  • Chronic Bronchitis




Chronic Obstructive Pulmonary Disease Treatment (COPD) Treatment Type Outlook




  • Drugs




    • Bronchodilator Monotherapy




      • Short-Acting Beta2-Agonists (SABAs)




      • Long-Acting Beta2-Agonists (LABAs)




      • Anti-Cholinergic Agent






    • Anti-Inflammatory Drugs




      • Oral And Inhaled Corticosteroids




      • Anti-Leukotrienes








  • Surgery




    • Lung Volume Reduction Surgery (LVRS)




    •  Lung Transplant




    • Bullectomy




    • Others






  • Oxygen Therapy




Chronic Obstructive Pulmonary Disease Treatment (COPD) End User Outlook




  • Hospitals & Clinics




  • Homecare Settings




  • Others




Chronic Obstructive Pulmonary Disease Treatment (COPD) Regional Outlook




  • North America






  • US




  • Canada






  • Europe






  • Germany




  • France




  • UK




  • Italy




  • Spain




  • Rest of Europe






  • Asia-Pacific




    • China




    • Japan




    • India




    • Australia




    • South Korea




    • Rest of Asia-Pacific






  • Rest of the World




    • Middle East




    • Africa




    • Latin America







Report Scope:

Report Attribute/Metric Details
Market Size 2021 USD 1.82 billion
Market Size 2022 USD 3.07 billion
Market Size 2030 USD 29.33 billion
Compound Annual Growth Rate (CAGR) 4.50% (2022-2030)
Base Year 2021
Forecast Period 2022-2030
Historical Data 2018 & 2020
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Type, Treatment Type, End User and Region
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled AstraZeneca (UK), Abbott Laboratories (US), Dr. Reddy’s Laboratories Ltd (India), GlaxoSmithKline (UK), F. Hoffmann-La Roche Ltd (Switzerland), Almirall (Spain), Boehringer Ingelheim (Germany), Pfizer Inc. (US), Novartis AG (Switzerland), Astellas Pharma (Japan)
Key Market Opportunities Increasing demand for home care therapeutic devices
Key Market Dynamics Rise in prevalence of CPOD across the globe Increase in adoption of more effective combination therapy


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The Chronic Obstructive Pulmonary Disease Treatment (COPD) market is anticipated to reach USD 29.33 billion at a CAGR of 4.50% during the forecast period of 2022 to 2030

The U.S Chronic Obstructive Pulmonary Disease Treatment (COPD) market share is 35-40% during the forecast period of 2022 to 2030

The Chronic Obstructive Pulmonary Disease Treatment (COPD) market is expected to register a CAGR of 4.50% during the forecast period of 2022 to 2030.

The North America held the largest market share in the Chronic Obstructive Pulmonary Disease Treatment (COPD) market

AstraZeneca (UK), Abbott Laboratories (US), Dr. Reddy’s Laboratories Ltd (India), GlaxoSmithKline (UK), and F. Hoffmann-La Roche Ltd (Switzerland)

The drugs segment led the Chronic Obstructive Pulmonary Disease Treatment (COPD) market

The Hospitals & Clinics end user led the Chronic Obstructive Pulmonary Disease Treatment (COPD) market